Although Apc mutation is widely considered an initiating event in colorectal cancer, little is known about the earliest stages of tumorigenesis following sporadic Apc loss. Therefore, we have utilized a novel mouse model that facilitates the sporadic inactivation of Apc via frameshift reversion of Cre in single, isolated cells and subsequently tracks the fates of Apc-deficient intestinal cells. Our results suggest that consistent with Apc being a 'gatekeeper', loss of Apc early in life during intestinal growth leads to adenomas or increased crypt fission, manifested by fields of mutant but otherwise normal-appearing crypts. In contrast, Apc loss occurring later in life has minimal consequences, with mutant crypts being less prone to either increased crypt fission or adenoma formation. Using the stem cell-specific Lgr5-CreER mouse, we generated different sized fields of Apc-deficient crypts via independent recombination events and found that field size correlates with progression to adenoma. To evaluate this early stage prior to adenoma formation as a therapeutic target, we examined the chemopreventive effects of sulindac on Apc-deficient occult crypt fission. We found that sulindac treatment started early in life inhibits the morphologically occult spread of Apc-deficient crypts and thus reduces adenoma numbers. Taken together these results suggest that: (i) earlier Apc loss promotes increased crypt fission, (ii) a field of Apc-deficient crypts, which can form via occult crypt fission or independent neighboring events, is an important intermediate between loss of Apc and adenoma formation and (iii) normal-appearing Apc-deficient crypts are potential unappreciated targets for cancer screening and chemoprevention.
Introduction
The prevailing dogma of solid tumor progression is that cancer results from the stepwise accumulation of multiple mutations beginning within a single cell (1) . In colorectal cancer, the adenomatous polyposis coli protein is frequently mutated in the earliest adenomas (1) and is the most commonly mutated gene in colorectal cancer (2) . However, little is known about the earliest stages of tumor initiation following Apc loss, in particular when loss occurs in isolated stem cells in an otherwise wild-type intestine. Mutation in a single stem cell alone may be insufficient to confer a tumorigenic phenotype and the local environment may play a modifying role by creating a field effect (3, 4) . The resulting numerical increase in mutant progeny will both raise the odds of further alteration and form a field of adjacent mutant crypts that could enhance tumorigenesis (5) . Field effects have been reported for genes such as p53 in esophageal cancer (6) , ulcerative colitis-associated neoplasia (7) and Cdh3 in colorectal cancer (8) . Here, we report for the first time evidence for field effects and occult crypt fission involving a strong tumor initiator, specifically the Apc gene, and how sulindac can inhibit the Apc-deficient crypt fission advantage, thereby reducing adenoma number.
A prevalent view is that Apc loss in intestinal crypt stem cells is sufficient for adenoma formation (9, 10) . However, our previous studies in which we examined the effects of Apc loss in single crypts surrounded by tissue expressing wild-type levels of Apc demonstrated a form of phenotypic plasticity. Namely, following Apc loss, adenoma formation could ensue, but the majority of Apc-deficient intestinal crypts retained a normal phenotype with increased clonal expansion (11) . In both cases (adenoma formation or field formation), Apc loss functions as a gatekeeper mutation with net increases in Apc-mutant cells (12) . Interestingly, a significant fraction of the morphologically normal Apc-deficient crypts exhibited a growth advantage resulting in clonal expansion and a field of mutant crypts, thus raising the possibility that crypt fission leading to an occult, horizontal spread of mutations is an important intermediate during tumorigenesis.
Here, we first show that the timing of Apc loss can affect field formation by strongly influencing the crypt fission advantage of Apcdeficient crypts, with later Apc loss resulting in decreased mutant field size and adenoma formation. Next, using the intestinal stem cell-specific Cre, Lgr5-CreER system (13, 14) , we generate different sized fields of Apc-deficient crypts and polyclonal adenomas, further substantiating that an expanded Apc-deficient field is important for adenoma formation (5, 15, 16) . Finally, we demonstrate that the non-steroidal anti-inflammatory drug (NSAID) sulindac can act as a chemopreventive by inhibiting the Apc-deficient occult crypt fission that appears to precede subsequent adenoma formation. Based on these findings, we suggest that: (i) isolated Apc-deficient crypts are not highly prone to tumorigenesis, whereas a field of Apc-deficient crypts formed by either occult crypt fission or independent neighboring events creates a local environment that is highly conducive to adenoma formation and (ii) minimizing Apc-deficient occult crypt fission is a previously unappreciated mechanism of chemoprevention. (18, 19) . Mice were housed in a specific pathogen-free High-efficiency particulate air filtered room and were fed a diet of Purina PicoLab Rodent Diet 20. The R26R and Lgr5-CreER (13) mouse strains were obtained from the Jackson Laboratory (Bar Harbor, ME). Tamoxifen (Sigma) was prepared in sunflower seed oil (Sigma) at a concentration of 10 mg/ml or 1 mg/ml. Two hundred microliters of the tamoxifen solution was intraperitoneally injected once into mice at the specified age. All experiments were approved by the Institutional Animal Care and Use Committee at Oregon Health and Science University. Genotyping was performed as described previously (11) and as described in the supplementary methods, available at Carcinogenesis Online. Lgr5-CreER; Apc
Materials and methods

Mice
580S/580S
; R26R-Confetti mice were generated and treated as described previously (14) . Intestinal organoids were cultured as described previously (20) .
Sulindac treatment
Sulindac was administered at different time points through the drinking water and continued until time of sacrifice. The sulindac solution comprised 180 mg/l of sulindac and 4 mM sodium phosphate dibasic in distilled water (pH ~7.4).
Scoring of β-gal
+ foci in wholemount intestine β-gal staining was performed and scored as described previously (11) . Nearby β-gal + foci were considered independent if not arising from the same crypt and surrounded by non-staining crypts. Adenomas, which involve multiple villi, and microadenomas involving a single villus were scored in wholemount and cross sections. We concentrated on the proximal small intestine for β-gal + foci counts because of inefficient recombination of the Cre reporter in the distal small intestine, as reported previously (21, 22) . The rate of cre reversion was determined by counting the number of colonies with β-gal + cells versus those without, as described previously (23) .
Abbreviations: MMR, mismatch repair; NSAID, non-steroidal antiinflammatory drug.
Results
Pms2
cre system for fate mapping of mutant intestinal stem cells To better understand the fates of normal and mutant intestinal cells, we developed the Pms2 cre mouse system that features an out-of-frame cre allele to stochastically recombine floxed target genes and the marker gene, β-gal ( Figure 1A ) (21) . This system enables not only the monitoring of tumor formation following stochastic genetic manipulations but also facilitates the tracking of normal or mutant stem cell fates. Replication slippage into frame is a function of cell division (DNA replication), and therefore Cre activation can occur any time after conception. Whereas Cre reversion will occur most often in any dividing cell, we stress that only the products of reversion events that take place in either intestinal stem cells (regardless of their position within the crypt) or long-lived progenitors will persist. Finally, we are able to alter the overall timing of Cre reversion by modulating the mismatch repair status, such that there is either a high frequency [Pms2 (Figure 2A and B ; R26R mice provides a baseline of how individual stem cells normally form clonal patches throughout life. Depending on the constellation of the Cre-target alleles, we can measure not only whether Figure 5 , available at Carcinogenesis Online). We also compared the number of β-gal + foci with the fraction of β-gal + foci that occupied more than one crypt (multicryptal) and found that >75% of the multicryptal β-gal + foci cannot be explained by independent, neighboring events (Supplementary Table 1 , available at Carcinogenesis Online). Overall, these results illustrate morphologic phenotypic plasticity of Apc-deficient crypts because early Apc loss increases clonal expansion (crypt fission) without necessarily resulting in visible adenoma formation.
In contrast to results with Pms2
cre/cre mice, we found that conditional alteration of Apc in Pms2 cre/+ mice results in significantly less subsequent crypt clonal expansion and adenoma formation ( Figure 2C Table 2 , available at Carcinogenesis Online). Interestingly, we observed a significant increase in the number of multicryptal β-gal + foci with age ( Figure 2D ), suggesting that a low level of crypt fission persists in the adult intestine. ; Apc CKO/CKO intestines. The percentage of transformed β-gal + foci was determined by scoring frozen sections counterstained with nuclear fast red. (D) The number of β-gal + foci containing more than three villi results in a linear regression of y = 0.004x + 0.2, which is a statistically significant increase with age (P < 0.001). The number of β-gal + foci containing more than three villi was determined via wholemount.
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Apc-deficient crypts have a greater chance of increased occult crypt fission. ; Apc CKO/CKO mice could be due to the higher level of background mutation in the MMR-deficient Pms2 cre/cre mice. Indeed, mice heterozygous for the Apc min mutation do in fact develop more adenomas in a MMR-deficient, Pms2 null background (25) . To compare the tumorigenic potential of isolated versus fields of Apc-deficient crypts independently of MMR status, we used the Lgr5-CreER mouse model (13) in combination with the conditional Apc CKO allele. Using this mouse model, we varied the frequency and field size of Apc-deficient crypts by altering the dose of tamoxifen given at similar times. The use of this system eliminates any effects of MMR status, removes possible differences based on timing of Apc loss and generates fields of Apc-deficient crypts from independent, neighboring events.
Both
We administered tamoxifen via intraperitoneal injection into mice at two doses, 2 mg/mouse (high) and 0.2 mg/mouse (low). The higher dose, similar to that used by other investigators (9) , resulted in 9.8% β-gal + crypts, whereas the lower dose resulted in 2.3% β-gal + crypts (P = 0.0001) ( Figure 4A ). Furthermore, with the higher dose, 56% (41/74) of β-gal + foci were multicryptal, of which 21% (16/74) comprised at least four neighboring β-gal + crypts. In contrast, the lower dose produced only 13% (17/127) multicryptal β-gal + foci (P < 0.001), with only 0.8% (1/127) comprising at least four neighboring β-gal + crypts (P < 0.001) ( Figure 4B ). These results show that varying the tamoxifen dose alters both the frequency and field size of recombined crypts.
Next, we injected Lgr5-CreER; Apc CKO/CKO mice with two different doses of tamoxifen. We used PCR to show that the conditional Apc allele was efficiently recombined in the intestine of mice injected with either the low or high dose of tamoxifen ( Figure 3C ). Whereas mice receiving the higher dose developed an average of 204 adenomas in the entire small intestine, we found that the lower dose tamoxifen resulted in an average of only seven tumors (P = 0.0002) ( Figure 4C) . Therefore, the lower tamoxifen dose resulted in a dramatic ~30-fold lower incidence of tumors while reducing the number of β-gal + crypts by only 4-fold and in turn increasing the proportion of isolated β-gal + crypts. Furthermore, by comparing the fold difference in β-gal + foci and tumors between the low and high dose, we estimate that three or more neighboring Apc-deficient crypts are needed for tumorigenesis ( Figure 4D) We predicted that large fields of mutant Apc-deficient crypts characteristically generated 'de novo' by high-dose tamoxifen administration should predispose to polyclonal adenomas because such fields should include numerous independent Apc loss events. Therefore, we analyzed adenomas from Lgr5-CreER; Apc
580S/580S
; R26R-Confetti mice 28 days after a single injection of high-dose tamoxifen (5 mg) (14) . In these 'Confetti' mice, adenomas arising from a single mutant cell should express only a single color, whereas adenomas arising from multiple independent mutant cells should display multiple color markers. As predicted, we found that a majority of adenomas (11/14) exhibited more than one fluorescent marker, illustrating that adenomas were mostly polyclonal, forming from multiple neighboring mutant crypts ( Figure 4E-G) .
Early administration of sulindac reduces the increased crypt fission and adenoma formation associated with early Apc loss
Because our present and previous (11) studies revealed the importance of mutant crypt clonal expansion for fostering adenoma initiation, we determined the effects of sulindac (26) on this early stage of tumorigenesis. Sulindac is an NSAID that reduces adenoma numbers in humans and mice (26) (27) (28) , with earlier exposure having an improved response (29) . We administered sulindac to Pms2 cre/cre ; Apc CKO/CKO mice (i) prior to conception-before any reversion events have occurred, (ii) at weaning-after early reversion events have occurred but before obvious adenoma formation or (iii) in the adult at 2 months of age-after most reversion events have occurred and adenomas have begun to form.
When sulindac was administered prior to conception via the mothers' drinking water and continued throughout life, the total number of β-gal + foci remained unchanged compared with untreated mice (P = 0.95), suggesting that sulindac did not noticeably eliminate Apc-mutant cells through apoptosis or alter the rate of Cre reversion. However, we did observe a reduction in the number of medium and large β-gal
; Apc CKO/CKO mice (P = 0.01 and P = 0.001) to levels similar to Pms2 cre/cre ; Apc +/+ control mice, consistent with sulindac suppressing the increased crypt fission associated with early Apc loss ( Figure 5D ). Furthermore, we observed in tissue sections that the percentage of multicryptal β-gal + patches returned to levels seen in the untreated mice when sulindac treatment was started at conception (Supplementary Figure 7A, Figure 5 , available at Carcinogenesis Online). Taken together, our results strongly suggest that crypt fission inhibition by sulindac was specific to Apc-deficient crypts. In addition to the suppressive effect on Apc-deficient crypt fission, sulindac treatment initiated prior to conception resulted in a 3-fold decrease in adenomas compared with untreated Pms2 cre/cre ; Apc CKO/CKO mice (P < 0.001) ( Figure 5D ). The inhibition by sulindac of both increased crypt fission and adenoma formation suggests a direct relationship and reinforces the idea that a field of Apc-deficient crypts is conducive to adenoma formation.
In stark contrast to 'preconception' administration, sulindac treatment initiated at weaning had no effect on the increased crypt fission associated with Apc loss, as evidenced by no significant reduction in the number of medium and large β-gal + foci compared with untreated mice (P = 0.82 and P = 0.94) ( Figure 5D ). Presumably, the growth advantage of Apc −/− crypts had already manifested prior to weaning. However, we did observe a slight reduction in adenoma number CKO/CKO mice injected with either the high or low dose of tamoxifen. Apc was recombined in both treatments. More importantly, the 3.6-fold increase in recombined Apc DNA with high-dose treatment was in agreement with the observed 4-fold increase in β-gal + crypts (see Figure 4A ).
(P = 0.02) ( Figure 5D ). Sulindac treatment initiated at 2 months of age failed to alter either the size distribution of normal-appearing Apcdeficient crypts (P = 0.99 and P = 0.39) or reduce adenoma number when compared with untreated mice (P = 0.93) ( Figure 5D ). These data show that similar to prior studies (29) , sulindac is most effective in reducing adenoma formation when administered early. In addition, sulindac does not appear to act only by eliminating Apc-deficient cells via increased apoptosis. Rather, our results suggest that sulindac can also reduce adenoma number by inhibiting the accelerated crypt fission associated with Apc loss and is most effective in reducing the tumor burden when Apc-mutant field size is minimized. Taken together, the sulindac results combined with the Pms2 cre and Lgr5-CreER data above suggest that adenomas arise most efficiently from a field of Apc-mutant crypts, which can form from either occult crypt fission or independent, neighboring events.
Discussion
In the current study, we have exploited Cre/lox systems in the mouse to alter Apc in the intestine. From our results, we offer some novel conclusions concerning intestinal tumor initiation and prevention. Specifically: (i) Sporadic Apc loss in single isolated cells does not Rather than 'instantaneous' transformation and a direct correlation between genotype and phenotype, our studies revealed considerable phenotypic plasticity with the majority of Apc-deficient single crypts retaining normal morphologic phenotypes. Although Apc is a driver mutation, we suggest that the local environment can influence the phenotype in Apc-deficient crypts. For example, the genome from a fully transformed melanoma cell can be completely 'reprogrammed' by nuclear transfer and contribute to the formation of a normal mouse (30) . However, we do show that Apc-mutant crypts are functionally abnormal because they can exhibit accelerated crypt fission, as manifested by increased numbers of larger mutant patches. Moreover, these advantages are more highly expressed during early development when intestinal growth by crypt fission is ongoing and mutant crypts can more readily outcompete normal crypts (31) . Once intestinal growth has slowed in the adult mouse, most phenotypically normal Apc-deficient cells have a reduced chance of displacing surrounding normal crypts because most mutant patches remain isolated. This observation is consistent with data from Apc Min/+ mice demonstrating that carcinogens administered early in life produce the highest numbers of adenomas (32) . Our data add to this concept and illustrate how early mutations are inherently better able to spread due to the normal crypt fission that occurs during growth.
We have utilized the MMR status of Pms2 cre mice to alter the frequency and time frame of Cre reversion. Compromised MMR in Pms2 cre/cre mice will result in both increased Cre reversion and a higher mutation rate throughout the genome. However, while an increased mutation rate could complicate our observations, we offer several reasons for why our data are not hindered by Pms2 deficiency. First, we compare Pms2-deficient experimental mice harboring floxed target genes with Pms2-deficient control mice that lack targets. Second, we analyze hundreds of reversion events per mouse, thus the stochastic nature of any 'background' mutations makes modifying a consequential gene in a significant fraction of β-gal + foci highly ; Apc CKO/CKO mice untreated (n = 6) or treated with sulindac started at conception (n = 8), 1 month (n = 6) or 2 months (n = 3). Sulindac treatment started prior to conception, via the mother's drinking water, resulted in a significant decrease in medium (4-9 villi) and large (10+ villi) β-gal + foci and tumor number compared with untreated Apc CKO/CKO mice. Sulindac started at weaning (1 month) resulted in a significant decrease in tumor number, but not β-gal + focus size. Sulindac started in adult mice at 2 months had no significant effect on β-gal + focus size or tumor number. Total β-gal + foci numbers and tumor numbers were determined in wholemount.
unlikely. Furthermore, Pms2-null mice are not prone to either intestinal adenomas or carcinomas (33) . Although we cannot rule out some undefined synergistic effect between the Cre targeted mutations and Pms2 deficiency, we believe such an effect is highly unlikely to play a significant role in influencing the phenotypes of Cre-expressing cells in Pms2 cre/cre mice. The idea that fields of mutant crypts can promote tumorigenesis was proposed previously to explain polyclonal adenomas often found in mice and humans heterozygous for Apc mutation (5, 15, 16) . Furthermore, tumor polyclonality was explained by short-range interactions between neighboring mutant crypts (34) . In contrast, other studies showed that intestinal adenomas could also be monoclonal and thus derived from single crypts (35) . Our data using the Pms2 cre system indicated that a field of Apc-deficient crypts originated in a single crypt followed by occult crypt fission. In addition, our results using the inducible Lgr5-CreER system showed that multiple independent, neighboring events can also produce a field that is conducive to the formation of polyclonal adenomas. Our analysis suggests that a field of at least three crypts is necessary for tumorigenesis. Therefore, we propose that adenomas can initiate by occult crypt fission and/or independent, neighboring events. Taken together, our results suggest that Apc-mutant fields, regardless of how formed, are conducive to adenoma formation. While our data are focused on intestinal cancer and Apc mutation, field effects have also been reported for other genes/cancers, such as p53 in esophageal cancer (6) , ulcerative colitis-associated neoplasia (7) and Cdh3 in colorectal cancer (8) . Field effects can manifest in a variety of ways, such as transcriptional and proliferative changes in benign prostate from prostate cancer patients (36, 37) , metabolic changes in non-dysplastic tissue from esophageal cancer patients (38) and methylation defects in the colonic mucosa from colorectal cancer patients (39) .
A phenotypically normal phase of mutant cells before tumorigenesis has important implications for human cancer progression. First, the lack of visible adenomas early in life in mice and humans with heterozygous germline Apc mutations is difficult to explain if adenoma formation requires a simple loss of the normal Apc allele in a single stem cell. Based on our findings, we propose that loss of the functional Apc allele regularly occurs but that phenotypic plasticity allows Apcdeficient mutant crypts arising early in life to accumulate and only subsequently evolve into adenomas during adolescence. For example, in familial adenomatous polyposis patients there are hundreds of visible monocryptal lesions that seem to progress through crypt fission (40) . Our data suggest that an even earlier stage in adenoma initiation is a phenotypically normal, but Apc-deficient crypt, which can remain normal for an extended length of time until a field of Apc-deficient crypts arises. Second, the large number of passenger mutations in human colorectal cancers implies that many mutations accumulate in normal intestine (41) . Indeed, it has been estimated that over half of all the mutations in a cancer accumulated in normal colon tissue (41) (42) (43) . Phenotypic plasticity facilitates the accumulation of both driver and passenger mutations throughout life as opposed to a simple stepwise progression, in which driver mutations accumulate only in visible tumors.
Because our studies with the Pms2 cre mice revealed the importance of mutant crypt clonal expansion for fostering adenoma initiation, we sought to determine the effects of a chemopreventive on this early stage before tumor progression. Sulindac is an NSAID that reduces adenoma numbers in humans and mice (26) (27) (28) (29) . Previous data from mice have led investigators to postulate that sulindac acts via stimulating apoptosis of Apc-deficient stem cells (44) . Such an apoptotic mechanism should result in a marked reduction in β-gal
Apc-deficient foci in our system. However, we found that the numbers of normal-appearing β-gal + ; Apc −/− foci were similar between treated and untreated mice. Interestingly, however, sulindac treatment resulted in smaller β-gal + ; Apc −/− foci. Therefore, we suggest that sulindac reduces adenoma numbers in the mouse not only by increasing apoptosis within the adenoma, as shown convincingly by previous investigators (44) , but also by limiting the increased crypt fission and subsequent mutant field formation associated with Apc loss. Sulindac may therefore block the gatekeeper function of Apc deficiency or the net increase in mutant cells. Elucidating the mechanism by which sulindac can inhibit increased crypt fission associated with Apc loss is worthy of further investigation.
In terms of human cancer prevention, low-dose NSAID (e.g. aspirin) use has been associated with significantly reduced colorectal cancer risk (45) , most often explained by increased apoptosis of Apcdeficient cells (46) (47) (48) . However, reductions in cancer risk require 5 or more years of aspirin use (49) , and the chronicity of use rather than the dosage appears to be critical for prevention (50) . These epidemiologic findings are difficult to explain if the only chemopreventive mechanism is by apoptotic elimination of mutant cells. An additional explanation, based on our findings with sulindac reported here, is that chronic low-dose NSAIDs limit the expansion of Apc-deficient cells, therefore reducing tumorigenesis by inhibiting the otherwise enhanced crypt fission of Apc-mutant cells (51) (52) (53) . As reported for Fig. 6 . Model for progression from an isolated Apc-deficient crypt to adenoma. First, an isolated stem cell loses Apc function during development of the intestine. Next, the Apc-mutant stem cell spreads by crypt succession to monoclonality. Possessing a selective advantage, the Apc-deficient crypt forms a field of mutant crypts via increased crypt fission. A field of Apc-deficient crypts is now primed to undergo tumorigenesis and produce an adenoma. Finally, sulindac blocks the crypt fission advantage of Apc-deficient crypts, thus preventing a field of mutant crypts from forming and hence tumorigenesis. Sulindac seems to have minimal effect on tumorigenesis after the field of Apc-deficient crypts has formed. adult humans (8, 54) , we observed continued crypt fission in adult mice ( Figure 2D ), albeit at a slower rate than during development (31, 55) . Because a low level of crypt fission persists in the adult, the possibility remains that new sporadic Apc mutations can accumulate in isolated crypts and over years create small fields of mutant crypts. The reduction in tumors after chronic aspirin use in humans could reflect the inhibition of the enhanced crypt fission of Apc-deficient crypts observed with sulindac in this study. This inhibition would reduce, but not completely prevent, any new field expansions of Apcdeficient crypts. In addition, fields of Apc-deficient crypts that were already established would not be eliminated. Therefore, we believe that our data can help explain why low-dose aspirin does not immediately reduce cancer risks, does not completely eliminate the chance of getting a tumor and requires at least 5 years of chronic administration to reduce the chance of cancer by 30-40% (45, 56) .
In summary, the ability to engineer and follow the fates of specific sporadic mutations in marked single cells has revealed both the phenotypic plasticity of Apc-mutant intestinal cells and the subsequent occult clonal expansion of mutant crypts via increased crypt fission. Such increased crypt clonal expansion by normal-appearing Apc-deficient crypts is consistent with the gatekeeper role of Apc but occurs without the microscopic or macroscopic manifestations of adenomas. Instead of a simple linear progression to cancer with genotype intrinsically associated with morphologic phenotype, our system reveals that the timing of mutation can influence morphologic phenotype, crypt fission and adenoma progression. Mutations can hitchhike and augment the crypt fission that occurs during normal growth and development. Most notably, the formation of a field of mutant crypts appears to be a more efficient tumor initiation pathway compared with the same mutations that remain isolated in single crypts. In addition, we find that limiting Apc-deficient occult crypt fission can serve as a previously unappreciated mechanism of chemoprevention ( Figure 6 ). Tables 1 and 2 
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